ERBB2 and breast cancer: SP also possessed oncogenic roles in breast cancer; it was overexpressed in breast cancer cell lines, facilitated bone marrow metastasis, and resulted in the transactivation of various receptors with tyrosine kinase activity such as Her2/neu and EGFR, thus enhanced breast cancer malignancy and metastasis and resistance to anticancer therapy [15, 19, 27, 28].